All In Biotech

Drug Trial Radar · NCT05751928

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.

Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 411 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

411

Actual

Start

Apr 5, 2023

Primary completion

Jan 2027

Study completion Jun 2027

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Mar 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, randomized, comparative phase III study, which will include subjects with resectable stage III skin melanoma (up to 3 resectable transient metastases are acceptable).

Conditions

  • Melanoma Stage III
  • Melanoma (Skin)

Interventions

  • BCD-217Biological

    BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting

  • anti-PD1Biological

    anti-PD1 agent in the adjuvant setting

  • Excision of the primary lesionProcedure

    Excision of the primary lesion will be performed per standard of care.

  • Regional lymphadenectomyProcedure

    Regional lymphadenectomy will be performed per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. event free survival (EFS)Time frame: 24 months

Locations

36 sites in 2 countries. Site status is shown where the registry gives one.

  • State Institution "Republican Scientific and Practical Center of Oncology and Medical Radiology named after A.I. N.N. Alexandrov"

    Lesnoy, Belarus

  • Healthcare Institution "Minsk City Clinical Cancer Center"

    Minsk, Belarus

  • State Institution "Mogilev Regional Oncological Dispensary"

    Mogilev, Belarus

  • Healthcare Institution "Vitebsk Regional Clinical Oncology Center"

    Vitebsk, Belarus

  • State Budgetary Healthcare Institution "Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine",

    Chelyabinsk, Russia

  • State budgetary healthcare institution Leningrad Regional Clinical Hospital

    Gatchina, Russia

  • State Autonomous Health Institution "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"

    Kazan', Russia

  • State budgetary health care institution "Kuzbass clinical oncological dispensary named after M.S. Rappoport"

    Kemerovo, Russia

  • Regional Goverment Budgetary Healthcare State "Kostroma Oncology Center"

    Kostroma, Russia

  • State Budgetary Institution of Healthcare "Leningrad Regional Clinical Oncological Dispensary named after V.I. L.D. Romana"

    Kuz'molovskiy, Russia

  • "Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • Branch of Hadassah Medical LTD Limited Liability Company

    Moscow, Russia

  • Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

    Moscow, Russia

  • Joint Stock Company "K31 City"

    Moscow, Russia

  • JSC "Medsi Group"

    Moscow, Russia

  • Moscow City Oncology Hospital No. 62

    Moscow, Russia

  • State budgetary health care institution of the city of Moscow "City Clinical Oncology Hospital No. 1 of the Department of Health of the City of Moscow"

    Moscow, Russia

  • Nizhny Novgorod Region State Budgetary Healthcare Facility "Clinical Diagnostics Center"

    Nizhny Novgorod, Russia

  • LLC "DobroMed"

    Novosibirsk, Russia

  • State Budgetary Healthcare Institution "Novosibirsk Regional Clinical Oncology Center" of the Novosibirsk Region

    Novosibirsk, Russia

  • Federal State Budgetary Institution "National Medical Research Center for Radiology" of the Ministry of Health of the Russian Federation

    Obninsk, Russia

  • Budgetary healthcare institution of the Omsk region "Clinical oncological dispensary"

    Omsk, Russia

  • JSC "Modern Medical Technologies"

    Saint Petersburg, Russia

  • Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)

    Saint Petersburg, Russia

  • City Hospital #40, Kurortny district

    Saint Petersburg, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State University"

    Saint Petersburg, Russia

  • Limited Liability Company "American Medical Clinic"

    Saint Petersburg, Russia

  • Limited Liability Company "Oncological Research Center"

    Saint Petersburg, Russia

  • Limited Liability Company "Strategic Medical Systems"

    Saint Petersburg, Russia

  • N.N. Petrov National Medicine Research Center of oncology

    Saint Petersburg, Russia

  • Private Medical Institution Evromedservis

    Saint Petersburg, Russia

  • Federal State Educational Institution of Higher Professional Education "Mordovia State University N.P. Ogareva "

    Saransk, Russia

  • State Health Care Institution "Volgograd Regional Clinical Oncology Dispensary № 1"

    Volgograd, Russia

  • Clinical Oncologic Dispensary No. 1

    Krasnodar, Krasnodar Kari, Russia

  • Clinical Oncologic Dispensary No. 2

    Sochi, Krasnodar Territory, Russia

  • Regional Clinical Oncology Hospital

    Yaroslavl, Yaroslavl Oblast, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.